Patents by Inventor Ian A. McDonald

Ian A. McDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8426587
    Abstract: The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: April 23, 2013
    Assignee: Pharmaxis Ltd.
    Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
  • Publication number: 20100298330
    Abstract: The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.
    Type: Application
    Filed: November 19, 2008
    Publication date: November 25, 2010
    Applicant: PHARMAXIS LTD.
    Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
  • Patent number: 6956049
    Abstract: In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 18, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Ian A. McDonald, Stephen D. Hess, Mark A. Varney
  • Patent number: 6632823
    Abstract: In accordance with the present invention, a novel class of substituted pyridine compounds (optionally containing ether, ester, amide, ketone or thioether substitutions) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of modulating acetylcholine receptors. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: October 14, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Jean-Michel Vernier, Nicholas D. P. Cosford, Ian A. McDonald
  • Patent number: 6316490
    Abstract: In accordance with the present invention, a novel class of substituted aryl compounds (containing ether, ester, amide, ketone or thioether substitution) that promote the release of ligands involved in neurotransmission have been discovered. In a particular aspect, compounds of the present invention are capable of modulating acetylcholine receptors. The compounds of the present invention are capable of displacing one or more acetylcholine receptor ligands, e.g., 3H-nicotine, from mammalian neuronal membrane binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jean-Michel Vernier, Ian A. McDonald
  • Patent number: 6017887
    Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: January 25, 2000
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
  • Patent number: 5969100
    Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: October 19, 1999
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
  • Patent number: 5877202
    Abstract: The present invention relates to novel indole derivatives useful in down-regulating estrogen receptor expression. Also included are methods for the treatment of neoplasms or of controlling the growth of a neoplasm in a patient afflicted with a neoplastic disease, especially estrogen-dependent neoplasms such as those associated with breast, ovarian and cervical tissue. Another embodiment of the present invention is a method of prophylactically treating a patient at risk of developing a neoplastic disease state. Also provided is a method for treating autoimmune diseases. Also included are pharmaceutical compositions of the novel indole derivatives.
    Type: Grant
    Filed: January 31, 1996
    Date of Patent: March 2, 1999
    Inventors: Alan J. Bitonti, Ian A. McDonald, Francesco G. Salituro, Jeffrey P. Whitten, Esa T. Jarvi, Paul S. Wright
  • Patent number: 5872101
    Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: February 16, 1999
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
  • Patent number: 5863902
    Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; RB is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: January 26, 1999
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
  • Patent number: 5723477
    Abstract: The present invention provides a class of pyridine compounds which are modulators of acetylcholine receptors, i.e., compounds which displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 3, 1998
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Patent number: 5710324
    Abstract: The present invention is directed to a new class of compound which are useful as inhibitors of the biosynthesis of nitric oxide.
    Type: Grant
    Filed: October 4, 1994
    Date of Patent: January 20, 1998
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Jeffrey P. Whitten, Ian A. McDonald, Laurie E. Lambert, Niall S. Doherty
  • Patent number: 5703100
    Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 30, 1997
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Patent number: 5606063
    Abstract: The present invention is directed to a new class of 4-sulfanimide-quinoline derivatives and to their use as NMDA antagonists.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 25, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Boyd L. Harrison, Bruce M. Baron, David M. Stemerick, Ian A. McDonald
  • Patent number: 5594011
    Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: January 14, 1997
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Ian A. McDonald, Jeffrey P. Whitten, Nicholas D. Cosford
  • Patent number: 5567710
    Abstract: In accordance with the present invention, there is provided a class of polycyclic fused ring compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: October 22, 1996
    Assignee: SIBIA Neurosciences, Inc.
    Inventors: Jeffrey P. Whitten, Ian A. McDonald, Jean-Michel Vernier
  • Patent number: 5559143
    Abstract: The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: September 24, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Ronald C. Bernotas, Mark W. Dudley, Jeffrey S. Sprouse
  • Patent number: 5547991
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: July 17, 1995
    Date of Patent: August 20, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz
  • Patent number: 5489579
    Abstract: The present invention is directed to a method for poteniating the therapeutic effects of selected NMDA antagonists.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: February 6, 1996
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Ian A. McDonald, Bruce M. Baron
  • Patent number: 5470870
    Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 28, 1995
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron